A series of new derivatives of estradiol substituted at position 17alpha by various aryls has been synthesized. This was made possible by efficient activation methods for the addition of aryllithiums to the carbonyl group at position 17 of estrone by using tetramethylethylenediamine (TMEDA) or BF3 x OEt2. Their relative binding affinity (RBA) for the alpha and the beta forms of the estrogen receptor (ER) have been measured. All except one of the compounds synthesized had an RBA value of around 10 % which indicates a level of tolerance towards the bulky substituent at position 17. The lipophilicity values measured for these compounds are higher than that found for estradiol (E2). A study of their proliferative/antiproliferative effects was carried out on hormone-dependent (MCF7) and hormone-independent (MDA-MB231) breast cancer cell lines. It is interesting to note that all the compounds are estrogenic. The possibility of easily attaching an iodine at the end of a phenyl spacer opens up a route to new radiopharmaceuticals for use in radioimaging.

6-(4-Methoxyphenyl)fulvene has been efficiently engaged in a process implying nucleophilic attack of methyllithium followed by a transmetallation reaction in the presence of different organorhenium sources {XRe(CO) 5 : X = Cl, Br, OTf; BrRe(CH 3 CN) 2 (CO) 3 , [BrRe(CO) 3 THF] 2 } to afford the corresponding cyclopentadienyltricarbonylrhenium-substituted compound. This study allowed us to determine the best complex for that transformation, and similar reaction conditions were used with success to provide new potential radiopharmaceuticals in the cold series. One of these compounds [the (4,4 -dihydroxybenzhydryl)cyclopentadienyltricarbonylrhenium] displays a good recognition for the α form of the oestrogen receptor.